Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Realty Income Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Realty Income Corp trades at $63.76 (market cap $59.47B). The key difference: Realty Income Corp is far larger — about 7.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Realty Income Corp pays a 5.1% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | O | |
|---|---|---|
Market Cap | $8.04B | $59.47B |
Sector | Health | Real Estate |
52-Week High | $339.75 | $67.56 |
52-Week Low | $241.71 | $55.93 |
Enterprise Value | $7.85B | $89.27B |
Dividend Yield | — | 5.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Realty Income (O) trades at $64.17, up 1.36% with a bullish technical outlook. The stock shows strong fundamentals with $5.75B revenue and 19.05% net income margin, though recent quarters have missed EPS estimates. Recent credit facility expansion to $5.5B supports growth initiatives, particularly in European markets. Dividend payments remain consistent at $0.27 quarterly, providing stable income for investors.
Outlook remains positive with analyst consensus target of $67.86 representing 5.8% upside. Risks include elevated P/E ratio of 51.89 and three consecutive quarterly earnings misses. The company's expansion strategy and strong cash flow generation support long-term growth potential, though valuation concerns warrant monitoring of future earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
